business / news / / Seeking Alpha
AbbVie hikes 2026 outlook as Skyrizi, Rinvoq offset Humira slump.
AbbVie raised its 2026 full-year earnings outlook due to strong Skyrizi and Rinvoq performance.
KEY POINTS
- Skyrizi and Rinvoq sales growth is now offsetting the decline in former best-seller Humira.
- AbbVie reported a Q1 2026 revenue that surpassed analyst expectations.
- AbbVie shares rose approximately 2% in premarket trading after the updated guidance announcement.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →